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Abstract: Resistance to clarithromycin and other antibiotics included in the eradication regimen,
such as amoxicillin and metronidazole, is important for Helicobacter pylori (H. pylori) eradication.
The aim of this study was to investigate the correlation between the results of antimicrobial
susceptibility testing and the eradication rate, as well as to understand the importance of antimicrobial
susceptibility testing in H. pylori eradication. We retrospectively reviewed the electronic medical
records of 1862 patients who underwent gastric biopsy for the culture of H. pylori during upper
endoscopy from March 2015 to June 2019. We tried to find a correlation between the results of the
antimicrobial susceptibility testing and the eradication rate in patients who received standard triple
or concomitant therapy. A total of 247 patients exhibited positive results for culture and underwent
antimicrobial susceptibility testing. Of these, 146 received eradication therapy, with follow-up tests
after treatment. In the standard triple therapy, patients who were susceptible to both clarithromycin
and amoxicillin exhibited significantly higher eradication rates (85.9%) than those susceptible to
clarithromycin and resistant to amoxicillin (75.0%) or those resistant to clarithromycin and susceptible
to amoxicillin (44.4%) (p = 0.013). In the concomitant therapy, patients who were susceptible to
both clarithromycin and metronidazole had significantly higher eradication rates (96.3%) than those
susceptible to clarithromycin and resistant to metronidazole (88.9%) or those resistant to clarithromycin
and susceptible to metronidazole (50.0%) (p = 0.016). There was a correlation between the results of
antimicrobial susceptibility testing and the eradication rate for H. pylori. In addition to clarithromycin,
susceptibility to amoxicillin and metronidazole is also important for the successful eradication of
H. pylori.
Keywords: Helicobacter pylori; eradication rate; antimicrobial susceptibility testing; standard triple
therapy; concomitant therapy
1. Introduction
Helicobacter pylori (H. pylori), which is a Gram-negative and spiral-shaped bacterium, is associated
with gastric diseases such as chronic gastritis, peptic ulcers, and gastric mucosa-associated lymphoid
tissue (MALT) lymphoma. Previous studies had shown H. pylori to be an independent risk factor for
gastric carcinogenesis [1–3]. Not only gastric cancer but also precancerous lesions such as intestinal
Antibiotics 2020, 9, 589; doi:10.3390/antibiotics9090589 www.mdpi.com/journal/antibiotics
Antibiotics 2020, 9, 589 2 of 10
metaplasia and atrophic gastritis were associated with H. pylori infection. Therefore, eradication
therapy is important for preventing the progression of precancerous lesions into gastric cancer.
A previous meta-analysis reported that the prevalence of H. pylori varied widely according to
geographic area [4]. The region with the highest prevalence of H. pylori was Africa (70.1%), with Oceania
demonstrating the lowest prevalence (24.4%). The prevalence was over 50 % in Eastern Asian countries
such as Korea.
In Korea, the eradication rate for standard triple therapy, which is considered the first-line
treatment, decreased by 76.4% in 2014 [5,6]. This unsatisfactory eradication rate was caused by several
factors including antimicrobial resistance and poor medication compliance [7,8]. Among these factors,
antimicrobial resistance is the main problem that prevents the successful eradication of H. pylori.
Specifically, a recent study showed that the resistance to clarithromycin is approximately 30% [9], and a
high resistance rate is one of the primary reasons for failure for H. pylori eradication.
Recent Korean guidelines regarding the treatment of H. pylori infections (updated in 2013)
emphasized empiric therapies such as standard triple therapy and bismuth-based quadruple therapy,
rather than tailored therapy based on antimicrobial susceptibility testing [6]. H. pylori culture and
antimicrobial susceptibility testing are difficult to routinely perform prior to treatment in clinical
practice, mainly because they are time consuming and costly, and require difficult conditions [10].
There are some established methods for detecting clarithromycin resistance such as dual priming
oligonucleotide–polymerase chain reaction and dual-labeled peptide nucleic acid probes [11,12],
but these methods are not widely used in clinical practice.
However, the Maastricht V/Florence Consensus emphasized the importance of antimicrobial
susceptibility testing before treatment [13]. According to this consensus, when the rate of resistance
to clarithromycin in the region is more than 15%, antimicrobial susceptibility testing before standard
triple therapy is recommended. This is more strict than the 15–20% threshold in the previous version
(Maastricht IV/Florence Consensus) [14].
Because antimicrobial resistance for H. pylori is challenging phenomenon for successful eradication
globally, there have been several studies on the antimicrobial susceptibility of H. pylori strains [15,16].
However, studies comparing in vitro antimicrobial susceptibility and the results of eradication
in vivo have been scarce. Therefore, the aim of this study was to investigate the correlation between
antimicrobial susceptibility testing and the eradication rate. Moreover, since the eradication regimen
for H. pylori consists of multiple antibiotics such as amoxicillin, clarithromycin, metronidazole,
and tetracycline [6,17], we focused on individual antibiotics consisting of two regimens and further
explored the importance of antimicrobial susceptibility testing for H. pylori eradication.
2. Materials and Methods
2.1. Study Design and Population
We retrospectively reviewed the electronic medical records of 1862 patients who underwent
gastric biopsy for H. pylori culture during upper endoscopy at the Gangnam Severance Hospital, Seoul,
Korea, from March 2015 to June 2019. Patients with positive results for H. pylori culture who underwent
antimicrobial susceptibility testing were enrolled in this study. All the enrolled patients were Korean
and were over 18 years of age.
The study protocol conformed to the ethical guidelines of the World Medical Association
Declaration of Helsinki and was approved by the Institutional Review Board of the Gangnam
Severance Hospital (3-2015-0193). Informed consent was not required, as this study was a retrospective
analysis of existing administrative and clinical data.
2.2. Data Collection
We retrospectively collected the data of enrolled patients, which included demographic, clinical,
and laboratory parameters. The demographic data included age, sex, height, body weight, body mass
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index (BMI), and personal and medical history. The clinical data included the eradication regimen
for H. pylori, medication compliance, and follow-up tests such as the urea breath test (UBT) and
rapid urease test (RUT). We checked patient compliance by retrospectively reviewing patient medical
records. To ascertain compliance, patients were required to bring their remaining pills after treatment,
which were counted. The laboratory data included antimicrobial susceptibility testing for antibiotics
included in the eradication regimen.
2.3. Isolation of H. pylori Strains and Growth Conditions
We collected gastric biopsy specimens during upper endoscopy. Biopsy specimens from antra and
corpora were placed in a transport medium. These specimens were seeded in egg yolk emulsion (EYE)
agar plates (Yuhan LabTech, Seoul, Korea). The EYE agar consisted of Columbia agar, 43.82 µg/mL;
EYE, 112.36 µL/mL; IsoVitaleX, 11.23 µL/mL; and 2,3,5-triphenyltetrazolium chloride, 45.0 µg/mL
(for colony staining). The plates were subsequently stored in a multigas incubator (microaerophilic
atmosphere: 10% carbon dioxide, 5% oxygen, and 85% nitrogen at 37 ◦C) for 3–7 days. If H. pylori
was not isolated after 7 days of incubation, the plates were incubated for 3 more days. H. pylori
isolates were identified on the basis of colony morphology and were confirmed by matrix-assisted laser
desorption/ ionization-time-of-fight mass spectrometry (MALDI-TOF) using the Microflex LT system
(Bruker Daltonics, Bremen, Germany). The measured profiles were compared to a profile hosted on a
database using the MALDI Biotyper 3.1 software (Bruker Daltonics). The colonies were re-identified
by subculture analysis.
2.4. Antimicrobial Susceptibility Testing
We performed antimicrobial susceptibility testing for five antibiotics, amoxicillin, clarithromycin,
metronidazole, tetracycline, and levofloxacin, which are all prescribed for H. pylori eradication.
Susceptibility to these antibiotics was determined by the Epsilometer test (E-test) [18]. The in vitro
minimum inhibitory concentrations (MICs) of the five antibiotics against the H. pylori clinical isolates
were defined by the points of intersection of the inhibitory zones with the strips. To determine
susceptibility, we adopted the European Committee on Antimicrobial Susceptibility Testing (EUCAST)
guidelines [19]. The MIC breakpoints for amoxicillin, clarithromycin, metronidazole, tetracycline,
and levofloxacin were >0.125, >0.5, >8, >1, and >1 mg/L, respectively. Multidrug resistance was
defined as resistance against two or more of the antibiotics evaluated.
2.5. Eradication Therapy for H. pylori
It takes a long time to identify the results of antimicrobial susceptibility testing after gastric biopsy.
Therefore, most of the patients in our hospital received empirical therapy for eradication. Moreover,
all the patients enrolled in this study received empirical therapy and had no history of eradication
therapy. The eradication regimen in this study included standard triple therapy, concomitant therapy,
and bismuth-containing quadruple therapy. Standard triple therapy involved the use of a proton-pump
inhibitor (PPI), amoxicillin, and clarithromycin. Concomitant therapy consisted of PPI, amoxicillin,
clarithromycin, and metronidazole. Bismuth-containing quadruple therapy consisted of PPI, bismuth,
metronidazole, and tetracycline. Patients who received eradication therapy underwent follow-up tests
to evaluate the success of the eradication.
2.6. Statistical Analysis
Continuous variable values are reported as the mean ± standard deviation, and categorical
variable values are reported as the number and percentage. We used the chi-square test or Fisher’s
exact test to compare the results of the antimicrobial susceptibility testing to the eradication rates
in patients who received standard triple therapy or concomitant therapy. Statistical analysis was
performed using SPSS version 23.0 (IBM Corp., Armonk, NY, USA). A two-tailed p-value < 0.05 was
considered statistically significant.
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3. Results
3.1. Flow Chart and Baseline Characteristics
Figure 1 shows a flow chart of this study. Of 247 patients, 61 were lost during follow-up and
7 refused eradication therapy. We retrospectively reviewed 179 patients who received empirical
eradication therapy and had no history of eradication. Among these 179 patients, 146 underwent
follow-up examinations such as UBT or RUT. Regarding compliance, all 146 patients took more than
80% of their prescribed medication. In addition, 77 patients received standard triple therapy, 43 received
concomitant therapy, and 26 received bismuth-containing quadruple therapy as a first-line therapy.
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Figure 1. Flo chart for the enrolled patients.
Of the 247 patients, 106 (42.9%) were men, and the mean age was 55.4 ± 11.8 years (Table 1).
The average BMI was 23.3 ± 3.4 kg/m2. Approximately 18.2% of patients were current smokers,
and 41.7% had alcohol consumption histories. Approximately 20.2% and 9.7% of the patients had
diabetes mellitus and hypertension, respectively. A total of 223 patients (90.3%) had a positive result
for RUT.
Table 1. Baseline characteristics of the study population.
Characteristics All Patients (n = 247)
Age (years, mean ± SD) 55.4 ± 11.8
Male (n, %) 106 (42.9)
Height (cm, mean ± SD) 163.2 ± 8.4
Weight (kg, ean ± SD) 64.1 ± 12.2
BMI (k / , n ± SD) 23.3 ± 3.4
Current s oker (n, %) 45 (18.2)
Alcohol history (n, %) 103 (41.7)
Diabetes mellitus (n, %) 50 (20.2)
Hypertension (n, %) 24 (9.7)
RUT, positive (n, %) 223 (90.3)
BMI, body mass index; RUT, rapid urease test.
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3.2. Results of Antimicrobial Susceptibility Testing
Figure 2 shows the antimicrobial resistance pattern of the H. pylori strains in this study. The rates of
resistance to amoxicillin, clarithromycin, and metronidazole were 10.1%, 29.6%, and 23.9%, respectively.
Furthermore, the rates of resistance to tetracycline and levofloxacin were 7.7% and 36.0%, respectively.
A total of 75 strains (30.4%) demonstrated multidrug resistance (5 for five drugs, 2 for four drugs, 15 for
three drugs, and 53 for two drugs).
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Figure 2. The anti icrobial resistance pattern of the Helicobacter pylori isolates (n = 247).
3.3. Eradication Rate for H. pylori
In this study, the total eradication rate was 86.3%. Among 77 patients who received standard
triple therapy, 62 had negative results in follow-up tests (eradication rate: 80.5%). Of the 43 patients
who received concomitant therapy, 38 achieved successful eradication (eradication rate: 86.4%).
All 26 patients who received bismuth-containing quadruple therapy achieved successful eradication
(eradication rate: 100.0%).
3.4. Comparison between Antimicrobial Susceptibility Testing and Eradication Rate
In standard triple therapy, patients who were susceptible to both clarithromycin and amoxicillin
had an 85.9% eradication rate. Patients who were susceptible to clarithromycin but resistant to
amoxicillin had a 75.0% eradication rate. Around 44.4% of the patients who were susceptible to
amoxicillin but resistant to clarithromycin achieved successful eradication (Figure 3A). This difference
in eradication rate was statistically significant (p = 0.013).
Figure 3B shows the results of antimicrobial susceptibility testing and the eradication rate with
concomitant therapy. For patients susceptible to both clarithromycin and metronidazole, the eradication
rate was 96.3%. Patients who were susceptible to clarithromycin but resistant to metronidazole had
an 88.9% eradication rate. Fifty percent of the patients who were susceptible to metronidazole but
resistant to clarithromycin achieved successful eradication. One patient who was resistant to both
clarithromycin and metronidazole had eradication failure. This result showed a significant difference
(p = 0.016). A comparison between the susceptibility status for all the antibiotics included in the regimen
(amoxicillin, clarithromycin, and metronidazole) and the eradication rate is shown in Appendix A.
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4. Discussion
Previous studies regarding H. pylori infection mainly investigated themes such as the results of
antimicrobial susceptibility testing and the comparison between empirical and tailored therapy [20,21].
These studies concluded that tailored therapy was superior to empirical therapy [20,22,23],
which suggests that antimicrobial susceptibility testing before treatment can be important for successful
eradication. However, these studies merely compared the eradication rates between empirical and
tailored therapy, without providing significant evidence. To the best of our knowledge, this is the first
study to identify the correlation between the susceptibility status for individual antibiotics included in
the regimen and the therapeutic outcome for H. pylori.
We determined that the rate of resistance to clarithromycin was 29.6%, which is higher than the
results from other studies. One recent Korean nationwide study reported 17.8% as the resistance rate
for clarithromycin [24]. This difference might be caused by several factors. First, the characteristics
of the geographic area might influence this result. Most patients in our study lived in a region with
high antibiotic prescription rates. Moreover, clarithromycin is a macrolide antibacterial agent that is
used for various infections in addition to H. pylori such as respiratory tract and skin infections [25].
Second, the MIC breakpoint is an important factor for this difference. The MIC breakpoint, which was
adopted in previous studies, was an inaccurate criterion [24,26,27]. This makes it difficult to compare
the resistance rate for clarithromycin or other antibiotics between studies.
Standard triple therapy and concomitant therapy are considered the first-line empirical regimens
in Korea in which antibiotics, such as clarithromycin, amoxicillin, and metronidazole, are combined
with a PPI. The clarithromycin susceptibility of H. pylori is a significant factor for successful
eradication. Molecular factors such as 23S rRNA mutation are the main mechanisms underlying this
resistance [28–30]. Although the precise mechanism underlying the resistance to other antibiotics is
unclear, several gene mutations such as rdxA, frxA, and fdxB (associated with metronidazole resistance)
and pbp1A (associated with amoxicillin resistance) have been reported [31–34]. We identified the degree
of importance for individual antibiotics included in the regimen, which is the strength of this study.
Among 77 patients who received standard triple therapy, 62 exhibited successful eradication
(eradication rate: 80.5%). We analyzed the eradication rate based on the results of antimicrobial
susceptibility testing for clarithromycin and amoxicillin. We divided the 77 patients into three groups.
The first group was susceptible to clarithromycin and amoxicillin, the second group was susceptible
to clarithromycin but resistant to amoxicillin, and the third group was resistant to clarithromycin
but susceptible to amoxicillin. The eradication rate was the highest in the first group (eradication
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rate: 85.9%), and the second group had a higher rate than the third group (p = 0.013). This suggests
that although the two antibiotics are important for eradication, clarithromycin is more effective
than amoxicillin.
Next, we analyzed the 43 patients who received concomitant therapy, and the eradication rate
was 86.4%. We also divided the 43 patients into three groups. The first group was susceptible to
clarithromycin and metronidazole, the second group was susceptible to clarithromycin but resistant to
metronidazole, and the third group was resistant to clarithromycin but susceptible to metronidazole.
We found that the first group had the best eradication rate (96.3%) and the third group had poorest
(50.0%) (p = 0.016). This indicates that although the two antibiotics are important for eradication,
clarithromycin is more effective than metronidazole.
This study has several meaningful messages for H. pylori eradication. First, it emphasizes
the importance of antimicrobial susceptibility testing. Although there are some commercial testing
kits for susceptibility testing for clarithromycin [11,35,36], they are not widely used. This study
demonstrates the necessity of a molecular testing kit. Moreover, this study also emphasizes the
importance of susceptibility testing for not only clarithromycin but also other antibiotics such as
amoxicillin and metronidazole. Therefore, a susceptibility testing kit for dual antibiotics is also required
for successful eradication. Second, we used a precise cutoff value for the MIC by adopting the EUCAST
guidelines. The observed resistance rates for antibiotics in H. pylori varied from those in previous
studies. This variation is associated with several factors, such as the characteristics of the geographic
area, method of susceptibility testing, and MIC breakpoint. Among these factors, the unification of the
MIC breakpoint is important for comparing the resistance rate across areas and according to the times.
There are two international guidelines for antimicrobial susceptibility testing, the EUCAST guidelines
and the Clinical and Laboratory Standards Institute (CLSI) guidelines. Regarding H. pylori, the MIC
breakpoint in the EUCAST guidelines was mentioned above. The MIC breakpoint for clarithromycin
is ≥1.0 mg/L, but the other four antibiotics evaluated do not have established breakpoints in the CLSI
guidelines [37]. However, the cutoff breakpoint values in previous studies were not exact [24,26,27].
This makes it challenging to evaluate the precise resistance rate. Therefore, this study is important, as
it provides a standard resistance rate when compared to other studies using the EUCAST guidelines.
Third, our study indicates that multidrug-resistant (MDR) strains, which have resistance against two or
more antibiotics, are important problems in successful eradication. The MDR rate was approximately
30.4% in our study. Moreover, in standard triple therapy and concomitant therapy, the eradication rate
was low for MDR strains. Recently, there were several studies regarding MDR in various infectious
diseases including H. pylori infection [38–40]. Based on the results of our study, future studies regarding
the mechanisms and new antimicrobial agents for MDR strains of H. pylori will be needed.
There were several limitations of our study. First, this was a retrospective study with a small
sample size of enrolled patients. Therefore, a prospective and large-scale study is warranted to clarify
the significance of our findings. Second, this study was not a nationwide study, and there was a selection
bias for the geographic area of the enrolled patients. However, we divided the enrolled patients into
three groups according to the susceptibility status in each regimen, and compared the eradication rates
between the three groups. Despite the small number and limited geographic characteristics of the
enrolled patients, we identified the trend of the susceptibility status for each antibiotic by grouping
the patients. Therefore, we believe that classifying patients into three groups was partially helpful in
overcoming these limitations.
5. Conclusions
A correlation was established between the results of in vitro antimicrobial susceptibility testing and
the in vivo eradication rate of H. pylori. In addition to clarithromycin—known to be an important factor
associated with eradication failure—other antibiotics such as amoxicillin and metronidazole—which
are included in the eradication regimen—are also important for the successful eradication of H. pylori.
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Appendix A
Table A1. Comparison between antimicrobial susceptibility testing and eradication rate in concomitant
therapy (n = 43).
Antimicrobial Susceptibility Testing
Number (%) of Successful Eradications
Clarithromycin Amoxicillin Metronidazole
S S S 23/24 (95.8)
S R S 3/3 (100.0)
S S R 8/9 (88.9)
S R R 0/0
R S S 2/4 (50.0)
R R S 1/2 (50.0)
R S R 0/0
R R R 0/1 (0.0)
S, susceptible; R, resistant.
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